Madrigal Pharmaceuticals (MDGL) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 3[1], 1 Phase 2[2].
Trial NCT03900429[4] evaluates MGL-3196 in NASH - Nonalcoholic Steatohepatitis with a target enrollment of 1759 participants. Trial NCT04951219[5] evaluates Resmetirom in Non-Alcoholic Fatty Liver Disease with a target enrollment of 1000 participants. Trial NCT05500222[6] evaluates Resmetirom in NASH with a target enrollment of 700 participants.
No Form 4 insider filings for MDGL were recorded at the SEC in the past 30 days[7].